“A delegation from Vabiotech, headed its director, Nguyen Anh Tuan, visited the Finlay Institute, where they discuss joint collaboration and future projects. The Vietnamese representatives were updated on the work of the Institution,” according to a message from the Cuban institute on the social network X.
“In the meeting between the Finlay Institute and Vabiotech, the desire to continue expanding collaboration between both biotechnology institutions was expressed,” the text says.
Vabiotech is one of Vietnam’s leading companies in the manufacturing, marketing, research and development of a wide range of vaccines, diagnostic kits, biological, therapeutic, and pharmaceutical products; cosmetics, and food, in addition to the provision of healthcare services.
Currently, Vabiotech produces four vaccines against hepatitis B, hepatitis A, Japanese Encephalitis and Oral Cholera, and imports immunogens to fight mumps, rubella, meningococcus and chickenpox.
Cuba’s Finlay Vaccines Institute has glycoconjugated, synthetic, combined, therapeutic and infectious disease injectables.
These products have a strong effect to control epidemics such as the one caused by Neisseria meningitidis in 1989 in Cuba, which was eradicated with the VA-MENGOC-BC.
A trivalent leptospirosis vaccine was also obtained from inactivated cells of Lectospira interrogans (serovars Canicola canicola, Pomona mozdok and Icterohaemorrhagiae copenhageni) to fight outbreaks of leptospirosis, among other scientific achievements that largely guarantee Cuba’s sovereignty in this field.